Skip to Content


In the US, Eptifibatide (eptifibatide systemic) is a member of the drug class glycoprotein platelet inhibitors and is used to treat Acute Coronary Syndrome, Angina, Heart Attack and Percutaneous Coronary Intervention.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Antiplatelet agent: Glycoprotein IIb/IIIa-receptor antagonist

Chemical Name

Cyclo(S-S)-mercaptopropionyl-(L) homoarginyl-glycyl-(L) aspartyl-(L) tryptophanyl-(L) prolyl-(L) cysteinamide

Foreign Names

  • Eptifibatidum (Latin)
  • Eptifibatid (German)
  • Eptifibatide (French)
  • Eptifibatida (Spanish)

Generic Names

  • Eptifibatide (OS: DCF, BAN)
  • C 6822 (IS)
  • Intrifiban (IS)
  • SB 1 (IS)
  • SCH 60936 (IS)

Brand Names

  • Clotide
    Biocon, India
  • Coromax
    USV, India
  • Eptifab
    AHPL, India
  • Eptifibatide Strides
    Agila, Bulgaria; Strides Arcolab, Poland
  • Eptifibatide Teva
    Teva, Israel
  • Integrilin
    Glaxo Group, Austria; Glaxo Group, Hungary; Glaxo Group, Iceland; Glaxo Group, Poland; GlaxoSmithKline, Switzerland; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Spain; GlaxoSmithKline, Finland; GlaxoSmithKline, Greece; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Ireland; GlaxoSmithKline, Italy; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, Portugal; GlaxoSmithKline, Romania; GlaxoSmithKline, Serbia; GlaxoSmithKline, Slovakia; GlaxoSmithKline Laboratoire Pharmaceutique, France; GlaxoSmithKline UK, United Kingdom; GSK, Belgium; Merck, Canada; Merck Sharp & Dohme, Hong Kong; Merck Sharp & Dohme, New Zealand; MSD, Thailand; Schering, United States; Schering-Plough, Argentina; Schering-Plough, Indonesia; Schering-Plough, Israel; Schering-Plough, Taiwan; Schering-Plough, South Africa; Scherring, Egypt
    GlaxoSmithKline, Sweden


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.